Biomx Inc logo

PHGE - Biomx Inc News Story

$6.5 0.1  1.7%

Last Trade - 09/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £258.5m
Enterprise Value £217.4m
Revenue £n/a
Position in Universe 3945th / 6827

BRIEF-Biomx Announces Positive Results Of A Phase 1A Pharmacokinetic Study For Inflammatory Bowel Disease/Primary Sclerosing Cholangitis Evaluating Delivery Of Oral BX002 Phage Therapy

Tue 2nd February, 2021 11:39am
Feb 2 (Reuters) - Biomx Inc  PHGE.A :
    * BIOMX ANNOUNCES POSITIVE RESULTS OF A PHASE 1A
PHARMACOKINETIC
STUDY FOR INFLAMMATORY BOWEL DISEASE/PRIMARY SCLEROSING
CHOLANGITIS (IBD/PSC) EVALUATING DELIVERY OF ORAL BX002 PHAGE
THERAPY
    * BIOMX - BX002 DEMONSTRATED SAFETY AND TOLERABILITY WITH
SUCCESSFUL DELIVERY OF A HIGH CONCENTRATION OF VIABLE PHAGE TO
LOWER GASTROINTESTINAL TRACT
    * BIOMX INC - EFFICACY RESULTS IN REDUCTION OF TARGET
BACTERIA
EXPECTED BY MID-2022 FROM PLANNED PHASE 1B/2A STUDY
    * BIOMX INC - IN PHASE 1A STUDY, BX002 WAS DEMONSTRATED TO
BE SAFE
AND WELL-TOLERATED, WITH NO SERIOUS ADVERSE EVENTS

Source text for Eikon:  ID:nBwc1x0X1a 
Further company coverage:  PHGE.A 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.